27. Aklief

Galderma Logo

Active ingredient: trifarotene
Disease: acne
Peak sales estimate: n/a
Approved: Oct. 4, 2019
Company: Galderma

The scoop: Aklief isn’t just a different formulation of an existing retinoid, it’s an entirely new retinoid molecule, the first to receive FDA approval for the treatment of acne in over 20 years. Two identical phase 3 studies on a total of 2,420 patients showed that the topical drug could reduce inflammatory lesions on the face in two weeks and on the back, shoulders and chest after four weeks, both significantly superior over the vehicle. The drug is also expected to be safer than older retinoids with fewer side effects such as application site irritation. The nod was the first one for Galderma as a standalone company after Nestlé exited skin health and spun it off to a consortium led by EQT Partners and the Abu Dhabi Investment Authority’s subsidiary Luxinva for CHF 10.2 billion. The company is now run by ex-Shire CEO Flemming Ornskov. — Angus Liu

27. Aklief

Suggested Articles

One day after its Opdivo-paired prospect flopped, Five Prime is farming out some preclinical antibodies to keep its clinical-stage pipeline alive.

The deal will see GSK pay $50 million and commit to $550 million in milestones for TCRs against two solid tumor targets identified by Immatics. 

Gilead has a new head of research biology: Michael Quigley, Ph.D., an alum of MedImmune, Janssen and Dana Farber, who joins from Bristol-Myers Squibb.